In patients with CAD, adding colchicine to evidence-based therapies reduces MACE without increasing adverse outcomes.
Where this comes from
- Record sourced from PubMed, PMID 33646848.
- Also identified by DOI 10.7326/ACPJ202103160-030.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Xia M, Yang X, Qian C. <b>Meta-analysis evaluating the utility of colchicine in secondary prevention of coronary artery disease.</b> Am J Cardiol. 2021;140:33-8. 33137319.
Medical subject headings
- Coronary Artery Disease